Maria Stracqualursi
Overview
Maria Stracqualursi counsels technology and life sciences companies from their formation through merger or acquisition.
She represents early-stage companies in venture capital and other financing transactions and also assists them with a variety of corporate law matters, including employment, equity compensation, consulting, confidentiality, restructuring, and corporate governance matters. Maria also has experience representing private companies in domestic and cross-border mergers and acquisitions.
Maria has assisted pro bono clients with name-change and asylum matters. She is proficient in Spanish.
Career & Education
- Corporate Associate, Boston-based firm
-
- Advised clients in equity and debt finance transactions
- Counseled startups with respect to formation, stock incentive plans and corporate governance
- Represented companies in mergers and acquisitions
-
- Corporate Associate, AmLaw 50 firm
-
- Represented technology companies in formation, financings, acquisitions, sales and other corporate transactions
-
- Corporate Associate, Boston-based firm
- Tufts University, B.A.
- Boston College Law School, J.D.
- New York
- Massachusetts
Maria's Insights
Firm News | 1 min read | 02.17.26
Crowell & Moring Advises GelMEDIX in $13 Million Seed Financing and Strategic Pharma Partnership
Boston – February 17, 2026: Crowell & Moring represented GelMEDIX, Inc., a biotechnology company focused on regenerative therapies for vision restoration, in the closing of its $13 million seed financing. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and additional investors. Alongside the financing, Crowell also advised on GelMEDIX’s first strategic collaboration with a global pharmaceutical company. Under the terms of the agreement, GelMEDIX will provide its hydrogel scaffold technology, which the partner will use in combination with several of its own cell lines to develop stem cell derived cell therapies.
Client Alert | 3 min read | 10.13.25
Representative Matters
- Preferred equity financings of numerous biotechnology companies focused on developing oncological therapeutics, immunology-based therapies, genetic disease treatments, and other critical life sciences innovations
Maria's Insights
Firm News | 1 min read | 02.17.26
Crowell & Moring Advises GelMEDIX in $13 Million Seed Financing and Strategic Pharma Partnership
Boston – February 17, 2026: Crowell & Moring represented GelMEDIX, Inc., a biotechnology company focused on regenerative therapies for vision restoration, in the closing of its $13 million seed financing. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and additional investors. Alongside the financing, Crowell also advised on GelMEDIX’s first strategic collaboration with a global pharmaceutical company. Under the terms of the agreement, GelMEDIX will provide its hydrogel scaffold technology, which the partner will use in combination with several of its own cell lines to develop stem cell derived cell therapies.
Client Alert | 3 min read | 10.13.25
Insights
Maria's Insights
Firm News | 1 min read | 02.17.26
Crowell & Moring Advises GelMEDIX in $13 Million Seed Financing and Strategic Pharma Partnership
Boston – February 17, 2026: Crowell & Moring represented GelMEDIX, Inc., a biotechnology company focused on regenerative therapies for vision restoration, in the closing of its $13 million seed financing. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and additional investors. Alongside the financing, Crowell also advised on GelMEDIX’s first strategic collaboration with a global pharmaceutical company. Under the terms of the agreement, GelMEDIX will provide its hydrogel scaffold technology, which the partner will use in combination with several of its own cell lines to develop stem cell derived cell therapies.
Client Alert | 3 min read | 10.13.25
